GlassScriptPhysician profile
Jennifer D Brody
NPI 1609862127
$10,138.73
in general payments reported to CMS, 2019-2025
25 companies · $5,799 in 2025
The $5,799 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,418 · 2020: $637 · 2021: $342 · 2022: $476 · 2023: $370 · 2024: $1,097 · 2025: $5,799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,179 · Travel and Lodging: $1,628 · Food and Beverage: $1,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,178.98 |
| Travel and Lodging | $1,627.85 |
| Food and Beverage | $1,459.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,181.13 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $1,078.79 | 2019-2024 | Opsumit, Uptravi |
| Glaxosmithkline, LLC. | $542.41 | 2019-2023 | Trelegy Ellipta, Arexvy |
| Grifols USA, LLC | $440.46 | 2019-2024 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.10 | 2019-2023 | Spiriva Respimat, Stiolto Respimat, Ofev |
| Abiomed | $265.44 | 2023-2024 | Impella |
| Mylan Specialty L.P. | $211.78 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $211.07 | 2019-2024 | Xarelto |
| Genzyme Corporation | $170.02 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $158.95 | 2019-2024 | Dupixent |
| Philips North America LLC | $104.79 | 2019-2023 | |
| Galvanize Therapeutics, INC | $100.91 | 2025 | Aliya System |
| Astrazeneca Pharmaceuticals LP | $80.72 | 2022-2024 | Fasenra, Airsupra |
| Verona Pharma, INC. | $50.80 | 2025 | Ohtuvayre |
| Gilead Sciences, INC. | $44.66 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $30.30 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $22.81 | 2019 | |
| Circassia INC. | $22.15 | 2019 | |
| Inspire Medical Systems, INC. | $21.80 | 2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $21.04 | 2019 | |
| Fisher & Paykel Healthcare INC | $16.52 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.93 | 2020 | |
| Insmed, INC. | $15.32 | 2019 | |
| Abbvie INC. | $13.33 | 2021 | |
| United Therapeutics Corporation | $2.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Brody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.